


**EASD****EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES**

ASSOCIATION EUROPEENE POUR L'ETUDE DU DIABETE . EUROPÄISCHE GESELLSCHAFT FÜR DIABETOLOGIE

Rheindorfer Weg 3 . D-40591 Düsseldorf . Germany . Tel: +49-211-7 58 46 90 . Fax: +49-211-75 84 69 29

E-mail: secretariat@easd.org . Homepage: <http://www.easd.org>**EASD****News Section****1/2006**

## **OFFICIAL ANNOUNCEMENT**

### **42nd Annual Meeting of the European Association for the Study of Diabetes**

#### **Copenhagen-Malmoe Denmark-Sweden**

**Thursday, 14 - Sunday, 17 September 2006**

Welcome to the EASD Copenhagen-Malmoe 2006.

On behalf of the Local Organising Committee, it is my great pleasure to invite you to attend and participate in the 42nd EASD Annual Meeting 2006, to be held in Copenhagen-Malmoe.

Copenhagen and Malmoe, the major cities in the Øresund region, are connected by a magnificent high-way bridge and tunnel. The Øresund region is the educational, scientific, and cultural power centre of Northern Europe with several universities, numerous pharmaceutical, biotech and medicotchnical industries, theatres, concert halls and interesting museums.

The venue of the EASD Copenhagen-Malmoe 2006 is the modern congress and exhibition site, the Bella Center. All scientific sessions will take place here. The Bella Center is easily accessible by train, metro and car from central Copenhagen as well as from Malmoe. It is situated close to the Copenhagen airport.

The Meeting will start with a get-together event at the Bella Center at 18:30 on Wednesday, 13 September, and the Meeting will end at 14:30 on Sunday, 17 September with the closing ceremony followed by a Farewell Reception. All registered participants and accompanying persons are cordially invited to these events.

We are confident that the EASD Annual Meeting in Copenhagen-Malmoe will become yet another unforgettable event. We hope you will enjoy not only an outstanding scientific programme, but also the vibrant atmosphere of the Øresund region and the two cities. **We look forward to seeing you in September 2006.**

With best regards,

Jørn Nerup

#### **1. LOCAL ORGANISING COMMITTEE**

President: Jørn Nerup

Vice Presidents: Leif Groop  
Birger Thorsteinsson

Secretary General: Ole Ortvad Andersen

Members: Bo Ahrén  
Knut Borch-Johnsen  
Bo Feldt-Rasmussen  
Sten Madsbad  
Martin Ridderstråle

Secretary Local Organising Committee:

Nina Meier  
42nd EASD Meeting  
Copenhagen-Malmoe  
Niels Steensens Vej 2  
DK-2820 Gentofte, Denmark  
Tel: +45-4443 9389  
Fax: +45-4443 8801  
E-mail:  
[Nina.Meier@easd-cph-malmoe.dk](mailto:Nina.Meier@easd-cph-malmoe.dk)  
[www.easd-cph-malmoe.dk](http://www.easd-cph-malmoe.dk)

## 2. PROGRAMME

ORIGINAL COMMUNICATIONS are invited on any subject relevant to the understanding of diabetes mellitus. Brief instructions are given in PARAGRAPH 4; for detailed instructions please refer to [www.easd.org](http://www.easd.org).

THE CLOSING DATE FOR ABSTRACTS IS 1 APRIL 2006. Communications must be delivered in English. There is no simultaneous translation. The Provisional Programme will be sent to all paid-up members of EASD in June 2006.

The programme will include the Opening Lecture by Professor Edwin Gale (UK), the 41st Minkowski Lecture, the 21st Camillo Golgi Lecture, the 38th Claude Bernard Lecture by Professor Leif C. Groop (Sweden), and State of the Art Lectures, Symposia, Oral and Poster Presentations.

**It is not permitted to take photographs and/or film during any of the sessions.**

## 3. RECEIPT OF ABSTRACTS

Abstracts can only be submitted online ([www.easd.org](http://www.easd.org)) and cannot be submitted LATER THAN 1 APRIL 2006. THIS DEADLINE WILL BE STRICTLY ENFORCED, as will the regulations given in paragraph 4. Acknowledgement of receipt will be sent via e-mail to the presenting (=first-named) author. Please contact the EASD Secretariat if no receipt of acknowledgement has been received by 10 April 2006.

## 4. SUBMISSION OF ABSTRACTS

Authors are not permitted to submit work that they know is likely to be published before the EASD Annual Meeting. The Programme Committee has the right to withdraw from the programme an abstract containing material that has already been published. EASD will consider abstracts that have been presented in recent months at local or national diabetes meetings. An author submitting or presenting already published work will be banned from presenting data at the EASD Meetings for three years.

### Abstracts submitted on Human Studies:

The box must be marked stating that the study has been reviewed by the Local Ethics Committee and that it has therefore been performed in accordance with the ethical standards laid down in the Helsinki Declaration (see World Medical Association: [www.wma.net](http://www.wma.net)).

### Abstracts submitted on Animal Studies:

The box must be marked stating that the study has been carried out along the "Principles of laboratory animal care" (NIH Publication no. 85-23, revised 1985) and according to the national law, if applicable.

Selection of abstracts for the Scientific Programme is made anonymously. **THE ABSTRACT MUST BE SUBMITTED** as follows:

**EACH PRESENTING AUTHOR** (=first-named author on the abstract) **CAN SUBMIT ONLY ONE ABSTRACT** (Presenting authors may be co-authors of other abstracts). It is **MANDATORY** that the first-named, presenting author of any abstract accepted for presentation, be present to deliver his/her paper. Failure to do so, without prior or adequate explanation sent to the EASD Secretariat by fax or e-mail, may result in the author being banned from presentation of future abstracts for three years.

Abstracts are welcome from non-members of EASD. Attention is drawn to paragraph 16 of this Official Announcement, regarding the date by which authors must become members of EASD, in order to qualify for preferential registration fees. These regulations will be strictly enforced.

Online Membership Application is possible by internet ([www.easd.org](http://www.easd.org)), but forms can also be downloaded or requested from the EASD Secretariat in Düsseldorf ([membership@easd.org](mailto:membership@easd.org)).

The abstract must be submitted in English. The authors should create an account using a login name and a password. With this information they can revise the submission as often as required, make changes, additions, amendments, change / add / delete authors, copy special characters easily into the text, re-write the abstract, download the text from a file or copy it into the submission box. All this is possible until the **Abstract Submission Deadline: 1 April 2006.** After this date the account will be closed. **CHANGES IN THE CONTENT OF THE SUBMITTED ABSTRACT WILL NOT BE ACCEPTED** after the submission deadline.

Detailed abstract submission instructions can be found under [www.easd.org](http://www.easd.org). These instructions for the submission of abstracts must be strictly followed. If an abstract is unsuitable for reproduction, it will be disqualified. The abstract should be submitted in the following way:

- 1) The title should be short (maximum 180 characters).
- 2) Please enter **your name** and the **names of co-authors** as given in the following example. It is **important to start each name with a capital letter and continue in lower case.**

Example:

First name: Jørn

2nd Initial: X

Surname: Nerup

- 3) The abstract must be structured. Begin each section with the words **Background and aims**:, **Materials and methods**:, **Results**: and **Conclusions**: in bold characters. One or two sentences should describe the **methods**, and any aspects of methodology (e.g. use of control groups, randomisation, patient selection, assay variation). The sentences stating the **results** must include hard data, including statistical analysis.
- 4) References are **not** allowed.
- 5) For drugs **exclusively generic names** should be used (no trademarks).
- 6) Abbreviations may not be used in the title. A list of approved abbreviations and units of expression for use without definition appears in DIABETOLOGIA, Vol. 49, 1, 2006.
- 7) Grant / Support information **should be entered** into the special field.
- 8) It is possible to select only one keyword.
- 9) Abstracts **CANNOT** be submitted as an **e-mail attachment**.
- 10) A **signed copy** of the abstract **must** be faxed to the EASD Secretariat in Düsseldorf **by 3 April 2006**:  
**Fax: +49-211-758 469 25 or +49-211-758 469 29.**

**In case of questions, please call: +49-211-758 469 20.**

## 5. KEYWORDS

One keyword from the list below should be selected for the submission:

### GROUP 1: Genetics / Epidemiology

- 01 Epidemiology
- 02 Genetics of type 1 diabetes
- 03 Genetics of type 2 diabetes
- 04 Monogenic forms of diabetes
- 05 Environmental factors (viruses, nutrients, toxins)

### GROUP 2: Islets

- 06 Developmental biology
- 07 Stem cells
- 08 Transcriptional regulation and protein synthesis
- 09 Insulin secretion in vitro and exocytosis
- 10 Beta-cell signal transduction
- 11 Beta-cell damage, degeneration and apoptosis
- 12 Other islet cells/hormones (IAPP, glucagon, somatostatin etc.)

### GROUP 3: Immunology/Transplantation

- 13 Experimental immunology and animal models of type 1 diabetes
- 14 Inflammatory mediators (cytokines, free radicals, chemokines)
- 15 Clinical immunology
- 16 Pancreas and islet transplantation
- 17 Prediction and prevention of type 1 diabetes

### GROUP 4: Pathophysiology/Metabolism

- 18 Insulin action
- 19 Insulin sensitivity and resistance
- 20 Insulin secretion in vivo
- 21 Hormone receptors
- 22 Gastro-entero pancreatic factors
- 23 Other hormones, action
- 24 Glucose transport
- 25 Carbohydrate metabolism
- 26 Protein metabolism
- 27 Lipid metabolism
- 28 Adipose tissue biology and adipocytokines
- 29 Weight regulation and obesity
- 30 Inflammation and type 2 diabetes
- 31 Prediction and prevention of type 2 diabetes
- 32 Animal models of type 2 diabetes and obesity
- 33 Other

### GROUP 5: Clinical Science and Care

- 34 Clinical diabetes
- 35 Nutrition and diet
- 36 Oral pharmacological agents
- 37 Hypoglycaemia
- 38 Exercise

### GROUP 6: Clinical Science and Care

- 39 Diabetes in childhood
- 40 Pregnancy
- 41 Insulin therapy
- 42 Devices
- 43 Health care delivery
- 44 Education
- 45 Psychological aspects
- 46 Socio-economic aspects
- 47 Information technology
- 48 Other

### GROUP 7: Complications

- 49 Neuropathy-somatic
- 50 Neuropathy-autonomic, incl. erectile dysfunction
- 51 Diabetic foot and skin disorders
- 52 Retinopathy
- 53 Nephropathy
- 54 Hypertension
- 55 Other

**GROUP 8: Complications**

- 56 Lipids, lipoproteins
- 57 Cardiac complications
- 58 Macrovascular disease
- 59 Glycation, AGE
- 60 Endothelium
- 61 Pathogenic mechanisms
- 62 Animal models with complications

**6. EASD Rising Star Symposium**

The **EASD Rising Star Symposium** aims to identify promising and innovative young researchers who are developing their research activities in Europe. Selected candidates will have the opportunity to present an overview of their past and ongoing research activities during a multidisciplinary research symposium at the 42nd EASD Annual Meeting in Copenhagen-Malmö. Four candidates will be selected, two in basic research and two in clinical research. Selected candidates will be invited by EASD to present a lecture (25 minute lecture + 5 minute discussion) and will receive a commemorative diploma. EASD will cover travel expenses, hotel and registration costs for the selected scientists.

**The Candidates:**

Candidates for the EASD Rising Star Symposium must be paid-up members of EASD and have a PhD, MD or equivalent degree. The candidates must be under the age of 35 (for basic research) or 37 years (for clinical research) on 1 January 2006. Preference will be given to individuals who normally reside in Europe and who have consistently pursued a well defined and innovative research line, leading to several publications in high impact peer reviewed journals.

The application to deliver a lecture at the **EASD Rising Star Symposium** should include:

- a. A two-page description of the applicant's research line, including supporting references to his/her publications, where appropriate.
- b. Full name, address, date of birth and brief curriculum vitae of the applicant (two pages maximum), plus complete list of publications.
- c. Proof of current EASD membership.
- d. Date and nature of the present appointment held by applicant.
- e. Letter of recommendation from the Head of the Department.
- f. Statement on whether the candidate wishes to apply in basic or clinical research (the basic and clinical tracks are evaluated separately).

Applications should be sent as an attached word / pdf document to:

EASD: [abstracts@easd.org](mailto:abstracts@easd.org), to arrive no later than 20 February 2006.

Selection of the 4 speakers will be made by the EASD Scientific Programme Committee. Applicants will be informed of the outcome of their application by the end of May 2006.

**7. PROGRAMME COMMITTEE**

The Programme Committee Members will meet in May 2006 and have the absolute right to accept or reject abstracts. Their decision is final. Only accepted abstracts will be printed. Presenting authors will be advised of the Programme Committee's decision by e-mail in the second week of June 2006.

**8. POSTER PRESENTATIONS**

Poster presentations rank equally with oral presentations at EASD Meetings. Posters must be displayed throughout the Meeting and should be mounted on the morning of the first day and removed at the end of the EASD Meeting. The Posters should be accessible for study at any time during the meeting hours.

Furthermore, all posters are presented at special, formal Poster Presentation Sessions which will be held on Thursday, Friday and Saturday from 12:45–14:45, when no other scientific sessions will take place. These Sessions offer an excellent opportunity for direct scientific exchange. During the Poster Presentation Sessions, the authors must be present or make arrangements for somebody with knowledge of the displayed work to be present at their posters. Reprints of the posters (sheets of DIN A4 format) should be made available and placed in the envelopes / cases which are attached to the poster boards. Detailed instructions will be sent to the presenting author on notification of acceptance.

**9. PROJECTION FACILITIES**

PowerPoint presentation via beamer will be available. Instructions on presentation will be sent to the presenting authors on notification of acceptance. Only single projection is provided.

## 10. VOLUME OF ABSTRACTS

Abstracts accepted for presentation will be published in the Volume of Abstracts and will be sent to EASD members prior to the EASD Annual Meeting. The Volume of Abstracts will be included in the conference bags. Furthermore, all accepted abstracts will be available on the Association's web site [www.easd.org](http://www.easd.org) before the Annual Meeting.

## 11. MEETINGS ON THE OCCASION OF THE ANNUAL MEETING

Other meetings held on the occasion of 42nd Annual Meeting of EASD will be announced by means of an ad-hoc programme, produced and distributed by the Local Organising Committee. Symposia held on the occasion of the Annual Meeting are not endorsed by EASD. For further information on symposia held prior to, or after, the official programme, please contact the President of the Local Organising Committee:

Professor Jørn Nerup, MD DMSc  
Steno Diabetes Center  
Niels Steensensvej 2  
DK-2820 Gentofte  
Denmark  
Tel.: +45 4443 9389  
Fax: +45 4443 8801  
e-mail: [nina.meier@easd-cph-malmoe.dk](mailto:nina.meier@easd-cph-malmoe.dk)  
[www.easd-cph-malmoe.dk](http://www.easd-cph-malmoe.dk)

## 12. CREDIT POINTS

Certificates of Continuing Medical Education Credit Points will be provided by the EASD Secretariat upon request at the EASD Annual Meeting.

## 13. TRAVEL GRANTS / STAYMENT GRANTS

Only EASD Members can apply for either a Travel or a Stayment Grant.

### Travel Grants - Deadline 1 May 2006

A limited number of Travel Grants will be available to PAID-UP MEMBERS OF EASD UNDER THE AGE OF 35 ON 1 SEPTEMBER 2006, who are presenting authors of accepted abstracts.

### Stayment Grants - Deadline 1 May 2006

A limited number of Stayment Grants will be available to PAID-UP MEMBERS OF EASD, who are presenting authors of accepted abstracts and who are living in countries facing financial problems.

### Application for Travel or Stayment Grants:

Application can only be made for one grant. The application for a Travel or Stayment Grant should consist of a SINGLE TYPE-WRITTEN PAGE giving the following information:

- a) Full name, date of birth and place of work of the applicant.
- b) EASD Membership number of the applicant.
- c) Date and nature of appointment to current position.
- d) Copy of submitted abstract.
- e) The cost of economy return fare between place of work and Copenhagen (in Euro).
- f) Brief recommendation by the Head of Department.

Applications for these Grants should be addressed to the Honorary Secretary of the Association and sent to EASD to ARRIVE NOT LATER THAN 1 May 2006. Applications received after this date cannot be considered!

EASD Secretariat  
Attn: Professor Decio L. Eizirik  
Rheindorfer Weg 3  
D-40591 Düsseldorf  
GERMANY

All applicants will be informed of the result of their application in June 2006.

## 14. PASSPORTS AND VISAS

A valid passport is generally required for entry into Denmark and Sweden. Being two of the Schengen countries (together with Austria, Belgium, Finland, France, Germany, Greece, Iceland, Italy, Luxembourg, The Netherlands, Portugal and Spain) Denmark and Sweden follow the common visa policy on short-term stays of up to three (3) months within the Schengen area. The citizens of Schengen countries are not subjected to border controls within the common area, though airlines or other carriers do require an identification document (e.g. ID or passport).

For more detailed information regarding visa requirements to enter Denmark and Sweden, please visit the website [www.udlst.dk/english/visa/default.htm](http://www.udlst.dk/english/visa/default.htm)

## 15. OFFICIAL INVITATIONS

Official letters of invitation to the 42nd Annual Meeting of EASD will be sent by the Local Organising Committee, upon request. Please note that this procedure aims to assist delegates who need to obtain a visa or permission to attend the Meeting and is not an official invitation covering fees and other expenses. It does not imply any financial support from the Meeting organisers. Requests should be addressed to the President of the Local Organising Committee:

Professor Jørn Nerup, MD DMSc  
Steno Diabetes Center  
Niels Steensensvej 2  
DK-2820 Gentofte  
Denmark  
Tel.: +45 4443 9389  
Fax: +45 4443 8801  
e-mail: [nina.meier@easd-cph-malmoe.dk](mailto:nina.meier@easd-cph-malmoe.dk)  
[www.easd-cph-malmoe.dk](http://www.easd-cph-malmoe.dk)

## 16. REGISTRATION

Preferably, registrations should be made by means of the secured online registration programme. However, a form to print out is also available on the Internet: [www.easd.org](http://www.easd.org).

Printed registration forms should be sent to:

EASD Secretariat  
- Registrations -  
Rheindorfer Weg 3  
D-40591 Düsseldorf, Germany  
Tel: +49-211-758 469 20  
Fax: +49-211-758 469 25  
E-mail: [registrations@easd.org](mailto:registrations@easd.org)  
[www.easd.org](http://www.easd.org)

Group-Registration  
For Group-Registration (10 or more delegates) please contact:

Regina Sautter  
EASD -Registrations- Düsseldorf  
Tel: +49-211-758 469 21  
Fax: +49-211-758 469 25  
E-mail: [Regina.Sautter@easd.org](mailto:Regina.Sautter@easd.org)

Press-Registration

Journalists are kindly requested to contact:

EASD -Registrations- Düsseldorf  
Tel: +49-211-758 469 20  
Fax: +49-211-758 469 25  
E-mail: [registrations@easd.org](mailto:registrations@easd.org)

Early registration closes on **30 June 2006** and any registration received after that date will be charged at the higher rate. Participants will receive confirmation of registration and payment. On arrival, participants must show this confirmation at the Registration Desk. Participants will receive their documentation and name badge, which **MUST BE WORN** due to safety regulations throughout the Meeting.

### REGISTRATION DESK - OPENING HOURS:

Tuesday, 12 September 2006	12:00 – 18:00
Wednesday, 13 September 2006	08:00 – 18:30
Thursday, 14 September 2006	08:00 – 18:00
Friday, 15 September 2006	08:00 – 18:00
Saturday, 16 September 2006	08:00 – 18:00
Sunday, 17 September 2006	08:00 – 13:00

### Participants' registration fees include:

- Admission to the Scientific Programme, 14 - 17 September 2006
- Admission to the Industry Exhibition, 14 - 17 September 2006
- Programme and Abstract Book
- Lunches on Thursday, Friday and Saturday, 14 - 16 September 2006
- Get-Together Party on Wednesday, 13 September 2006
- Closing Ceremony and Farewell Reception on Sunday, 17 September 2006
- Scandinavian Culture and History Nights: 14 September 2006 - Museums' Night  
15 September 2006 - Design and Music in town
- Conference bag

### Accompanying person's fees include:

- Get-Together Party on Wednesday, 13 September 2006
- Closing Ceremony and Farewell Reception on Sunday, 17 September 2006
- Scandinavian Culture and History Nights: 14 September 2006 - Museums' Night  
15 September 2006 - Design and Music in town
- Conference bag

## 17. REGISTRATION FEES (in EURO)

	Until 30 June 2006	1 July – 25 August 2006 and on-site
Paid-up member under 35 years of age on 1.1.2006	Euro 50.00	Euro 160.00
Paid –up member between 35-45 years of age on 1.1.2006	Euro 140.00	Euro 320.00
Paid-up member over 45 years of age on 1.1.2006	Euro 180.00	Euro 400.00
Non-member of EASD	Euro 550.00	Euro 700.00
Accompanying person *	Euro 150.00	Euro 150.00

\* Accompanying persons have no access to the scientific programme or industry exhibition.

All rates are indicated in Euro. The term “Paid-up member” refers to persons who are recorded at the EASD Secretariat in Düsseldorf as paid-up members at the time of the EASD Meeting. Annual membership payments received after **1 August 2006 from NEW MEMBERS** will **not** entitle them to registration fees for members. Please bring your membership card to the EASD Meeting.

Registration will close on 25 August 2006. For registrations after this date, please contact the On-site Registration counter.

## 18. PAYMENT OF REGISTRATION FEES

Please register online at [www.easd.org](http://www.easd.org) (secured site) and mark the method of payment.

### a) Credit Card (only VISA, EuroCard / MasterCard; all other cards will not be accepted)

Card number with expiry date, billing address and cardholder’s name are needed.

### b) Bank Transfers regarding registration have to be made to:

Account Holder: **EASD - Registrations -**  
 Account Number: **8 126 468 05**  
 Bank Code (BLZ): **300 700 24**  
 Bank: **Deutsche Bank**  
 Ritastr. 2  
 D-40589 Düsseldorf, Germany  
**IBAN (for Europe):** DE94 3007 0024 0812 6468 05  
**BIC / SWIFT:** DEUTDE33  
**(for Overseas)**

Please ensure you **mention the registered person’s name as reference** on the transfer.

### c) Cheques in Euro, drawn on a German Bank, payable to **EASD Registrations** and sent together with (a copy of) the registration form to:

EASD Secretariat  
 - Registrations -  
 Rheindorfer Weg 3  
 D-40591 Düsseldorf, Germany

Please indicate “EASD Registration 2006” and the name of the participant(s) on the cheque.

Other forms of payment different to those listed above will not be accepted.

**All charges due to bank transfers have to be paid by the sender. The name and address of the sender have to be marked clearly on every remittance!**

When the appropriate fees have been received, delegates will receive confirmation, which should be presented at the registration desks in Copenhagen. If you do not use the Online Registration System, please submit your Registration Form and payment by regular mail or fax. In order to avoid double charges, only send the registration form **ONCE**. If confirmation has not been received after 4 weeks, please contact:

EASD Registrations  
 Tel: +49-211-758 469 20  
 Fax: +49-211-758 469 25  
 E-mail: [registrations@easd.org](mailto:registrations@easd.org)

## 19. HOTEL ACCOMMODATION

A large number of hotels varying both in category and in location has been reserved on the occasion of the EASD 42nd Annual Meeting. Delegates are invited to choose a hotel which best suits their accommodation needs. However, due to the ever-increasing number of participants at the Annual Meetings, it is strongly advisable to book your room(s) at the earliest possible opportunity.

Hotel rooms are booked on a ‘bed and breakfast’ basis, including all local taxes. Youth hostel accommodation will be available as indicated in the hotel room rate scale below.

HOTEL CATEGORY	RATES PER ROOM B/B EURO
Deluxe	420–550
4 star	210–340
3 star	125–250
2 star	80–110

Accommodation will be offered on a “first come-first served” basis and will be offered online at [www.easd-cph-malmoe.dk](http://www.easd-cph-malmoe.dk)

Online booking is available at [www.easd-cph-malmoe.dk](http://www.easd-cph-malmoe.dk) from April 2006. A number of hotel rooms in different price categories has been blocked in Copenhagen, Malmoe and surrounding areas at preferential rates for the 42nd EASD Annual Meeting Copenhagen-Malmoe 2006.

As a service for individual participants, NHG A/S will arrange your hotel accommodation at no extra charge. The hotel rooms have been placed in four categories, based on price range and standard. Each category has a minimum and a maximum rate based on single/double occupancy. All hotels offer, as a minimum, bath/shower/WC, telephone, TV and breakfast facilities.

Due to limited room availability in Copenhagen, we recommend early bookings for hotel reservations. Rooms will be allocated on a first-come, first-served basis. After 14 June, 2006, NHG A/S cannot guarantee a hotel room nor the preferential rate, although NHG A/S will make every effort to meet participants' requirements.

Please note that some hotels require full pre-payment no later than 14 June, 2006. You will be duly informed if you have been booked into one of these hotels.

NHG A/S  
Att.: Christella Orup Rosenstrøm  
Vestre Gade 18  
DK-2605 Broendby  
Denmark  
Tel: +45 70 22 70 39  
Fax: +45 70 22 70 78  
E-mail: [christella@nhg.dk](mailto:christella@nhg.dk)  
[www.easd-cph-malmoe.dk](http://www.easd-cph-malmoe.dk)

## 20. SOCIAL EVENTS

(included in the Registration Fees of participants and accompanying persons)

### Get-Together Party

The Get-Together party will take place on Wednesday, 13 September 2006 at 18:30 hrs (snacks and drinks will be served).

### Opening Ceremony

The "EASD 2006 Opening Ceremony" will take place on Thursday, 14 September 2006 at 9:00hrs and will be, followed by the Opening Lecture.

### Scandinavian Culture and History Nights:

Thursday, 14 September 2006 between 19:00 and 22:00 hrs  
Several museums will be open  
Friday, 15 September 2006 between 18:30 and 21:00 hrs  
Design and Music in town  
For details please check: [www.easd-cph-malmoe.dk](http://www.easd-cph-malmoe.dk)

## Closing Ceremony

The Closing Ceremony will take place at the Congress Venue on Sunday, 17 September 2006 at 13:30hrs and will be, followed by a Farewell Reception.

## 21. OPTIONAL SOCIAL EVENTS

Copenhagen and Malmoe have three operas, many theatres and concert halls. Most of the year concerts (classic, jazz, rock) are offered. For further information and booking please visit:

<http://www.billetnet.dk> (Copenhagen)  
<http://www.billetnet.dk/search.jhtml?geography=4> (Malmoe)

## 22. INDUSTRY EXHIBITION

An Industry Exhibition will be held at Bella Center. For further details, including technical issues, please contact:

NHG A/S  
Att. Charlotte Andersen  
Vestre Gade 18  
DK-2605 Broendby  
Denmark  
Tel: +45 70 22 70 38  
Fax: +45 70 22 70 78  
e-mail: [charlotte@nhg.dk](mailto:charlotte@nhg.dk)

## 23. ITALIAN DELEGATES

Please note that Italian organisations wishing to sponsor the participation of Italian doctors should present their applications through our official agency, which will forward them to the Italian Health Ministry. Our agent's details are as follows:

Mr. Franco Cambria  
General Manager  
Fargo International  
Via Pietro Maroncell, 44/46  
I-50137 Firenze  
Italy  
Tel: + 39 055 600 555  
Fax + 39 055 609 078

## 24. GROUP HOTEL RESERVATIONS

Special reservation procedures apply to hotel group bookings. For bookings of more than 10 rooms please contact:

NHG A/S  
Att. Christella Orup Rosenstrøm  
Vestre Gade 18



DK-2605 Broendby  
Denmark  
Tel: +45 70 22 70 39  
Fax: +45 70 22 70 78  
e-mail: christella@nhg.dk

## **25. CANCELLATION POLICY**

### **1. Cancellation of Registration**

Refund of registration fees will be as follows:

- received before 30 June 2006: 100% refund (minus Euro 50 handling fee)
- received between 1 July and 31 July 2006: 50% refund (minus Euro 50 handling fee)
- no refund on cancellations received after 31 July 2006

### **2. Cancellation of Hotel Accommodation**

#### **Individual Bookings:**

Total cancellations are permissible free of charge when the cancellation is made in writing to NHG no later than 15 August 2006. Paid deposits will be refunded minus a handling fee of DKK 150 per cancelled room.

After 15 August 2006, cancellations or no-shows will be charged for the entire booked period. NHG reserves the right to charge any outstanding amount to the given credit card.

The deadline for any name, arrival or departure changes is 26 August 2006. After this date, it is not possible to make any changes to the individual accommodation.

All cancellations and changes are only valid when made in writing and confirmed by both parties.

Cancellation terms are also available at <http://www.easd-cph-malmoe.dk> under "Hotel Accommodation".

#### **Group Bookings:**

Total cancellations are permissible free of charge when the cancellation is made in writing to NHG no later than 14 May, 2006. Paid deposits will be refunded minus a handling fee of DKK 200,00 (~€ 27) per cancelled room.

For cancellations made later than 14 May, 2006, the following rules apply:

Between 15 May and 14 June, 2006, a maximum of 30% of the originally booked rooms can be cancelled (handling fee as above).

Between 15 June and 14 August, 2006, up to 10% of last given number of rooms can be cancelled. (Handling fee as per above).

After 15 August 2006, cancellations or no-shows will be charged in full.

The deadline for name changes is 1 September, 2006. All name changes done after this date will be charged a handling fee of DKK 200 (~€ 27) per change.

Reduction / cancellation is only valid when in writing and signed by both parties.

For cancellations exceeding the above-mentioned percentages the full amount for the booked period will be charged. However, the appointed local agent NHG will try to resell such rooms.

All no-shows will be charged in full.

### **3. Cancellation of Social Events / Tours**

Cancellation terms for tours and social events will soon be available at <http://www.easd-cph-malmoe.dk> under "Events".

**All refunds will be processed after the Annual Meeting.**

## **26. TRAVEL TO BELLA CENTER**

Official Carrier:

SAS Star Alliance is the official congress carrier offering a global route network linking Copenhagen-Malmoe with a great many cities around the world. For attendees travelling to Copenhagen-Malmoe special airfares are available. For details please contact the SAS Star Alliance nearest to you and refer to:

Event code: SK112S6

Event date: 12 SEP – 17 SEP 2006

On request you may have to present proof of your registration.

## **27. LOCAL TRANSPORTATION**

**Bus**

Bus 30

Vesterport Station via Copenhagen Central Station - direction Copenhagen Airport (international), stops at Bella Center

**Metro**

Metro M1  
Direction Vestamager

Take M1 to the Bella Center metro stop.  
For further information: <http://www.m.dk>

**Regional train**

From Copenhagen Airport and Malmø:

Take the train to Ørestad Station (Direction Copenhagen Central Station) and change to Metro M1 to the Bella Center Metro Station - direction Vanløse

From Copenhagen Central Station – direction Copenhagen Airport or Malmø and from Malmø Central Station – direction Copenhagen Airport or Copenhagen Central Station:

Take train to Ørestad Station and change to Metro M1 to the Bella Center Metro Station - direction Vanløse

Plan your trip to the Bella Center by bus, train or metro on <http://www.rejseplanen.dk>

**Car**

The Bella Center is conveniently located by the highway connecting Denmark and Sweden. Follow the “Lufthavnsmotorvejen” sign, on route no. 20. Take exit 19 to Center Boulevard. Sign says “Ørestaden” in bold print and “Bella Center” below in small print.

**Taxi**

- Fare from Bella Center to downtown is approx. DKK 115 (~€ 16)
- Fare from Bella Center to Copenhagen Airport is approx. DKK 100 (~€ 14)
- Fare from Copenhagen Airport to Copenhagen City is approx. DKK 150 (~€ 21)
- Fare from Copenhagen Airport to Malmø City is approx. SEK 620 (~€ 66)

- Fare from Bella Center to Malmø City is approx. SEK 860 (~€ 92)
- Fare from Copenhagen Airport to Lund is approx. SEK 830 (~€ 88)

Exchange rates: 1 Euro = approx. 7.5 DKK / 10 SEK

**28. INSURANCE**

The registration fees do not include insurance of participants against accidents, sickness, cancellation, theft, property loss or damage. Participants are advised to take out adequate personal travel insurance.

**29. DISCLAIMER**

All efforts will be made in order to adhere to the programme as printed. However, EASD 2006 and its agents reserve the right to alter or cancel, without prior notice, any of the arrangements, timetables, plans or other items relating directly or indirectly to the Meeting, for any case beyond their reasonable control. EASD 2006 and the Local Conference Organisers are not liable for any other loss or inconvenience caused as a result of such changes.

**30. TOURS**

NHG A/S will offer a wide range of congress tours and excursions to accompanying persons before, during and after the Meeting. For more details please visit the following web site: <http://www.easd-cph-malmoe.dk> under “Events”.

NHG A/S

Att.: Pernille Halken or Carolina S. Kromann

Vestre Gade 18

DK-2605 Broendby

Tel: +45 70 222 130

Fax: +45 70 222 140

E-mail: [halken@nhg.dk](mailto:halken@nhg.dk) or

[carolina@nhg.dk](mailto:carolina@nhg.dk)

<http://www.easd-cph-malmoe.dk>

## **Report of the 9th Spring Scientific Meeting of the EASD PsychoSocial Aspects of Diabetes (PSAD) Study Group 22–24 April 2005**

The 10th Spring Scientific meeting of the Psychosocial Aspects of Diabetes (PSAD) Study Group of the European Association for the Study of Diabetes (EASD) took place in Wuerzburg, Germany this year. This conference focussed on the key issues of prevention of diabetes, depression in diabetes and quality of life, highlighting state of the art knowledge and presenting the most recent psychological findings in the field.

As always the meeting commenced with the Anita Carlson Memorial Lecture, delivered this year by Professor Edwin Gale (University of Bristol, England and Editor-in-Chief of *Diabetologia*) and entitled “Ten thousand people with diabetes and me: medication versus motivation in the management of diabetes”. Based on the example of the Hawthorne effect Professor Gale demonstrated that besides pure efficacy there must be an understanding of the mediating mechanisms between any intervention and its effect. Otherwise scientific endeavour might be endangered by drawing premature conclusions about cause-effect relationships.

Diabetes is fast becoming epidemic. Fortunately this dramatic development is not an unavoidable fate. Research has shown that we are able to reduce the risk of developing diabetes through changing the lifestyle of people who are at risk for diabetes. Thus lifestyle changes are a matter of importance for which psychological aspects should be considered and psychological principles and techniques applied. One symposium was dedicated to diabetes prevention and was chaired by Dr Mirjana Pibernik-Okanovic (Croatia).

Dr Elizabeth Walker (USA) presented subsequent analyses from the Diabetes Primary Prevention Trial (DPP) about the relevance of risk perception and health outcomes in persons at risk for diabetes. Interestingly, the data suggested that there was a U-shape relationship between the comparative risk perception for the development of diabetes and the actual occurrence of the disease. Persons with a higher or lower perceived risk for the development had an increased likelihood of getting diabetes, compared to persons with an intermediate risk assessment.

Dr Marlene Kritz (UK) presented her study about the effectiveness of brochure information on symptoms and risk factors for type 2 Diabetes. In a high risk population less than 2% were aware of their actual risk level of developing diabetes. Although medical advice on diabetes risk was the most significant predictor of

enhancement of risk perception, this advice did not result in a greater readiness for screening examination. But individuals who read a brochure information (“Are you at risk for diabetes”, developed by Diabetes UK) were 3 times more likely to subsequently screen for diabetes than the control group, which received no written information. This study clearly demonstrates that even simple measures are able to improve early detection of persons at risk for diabetes.

The DAWN (Diabetes Attitudes Wishes and Needs) study provided an insight into the perspectives of primary care physicians and diabetologists on diabetes prevention. Prof Mark Peyrot (USA) pointed out that general practitioners as well as diabetes specialist stressed the relevance and need for diabetes prevention but missed programmes to realise diabetes prevention in clinical care.

Since diabetes therapy is aiming at an optimal quality of life, which implies prevention of acute and late complications as well as psychological well being, knowledge about both measurement and the determinants of quality of life in people with diabetes is an important consideration for clinical diabetology. Therefore one session chaired by Dr Cathy Lloyd (UK) was devoted to these questions.

Bart Toolen (The Netherlands) studied the impact of intensive care vs. usual care in newly diagnosed (screen detected) type 2 diabetes on psychological outcomes. Intensive care patients with a very short diabetes duration (< 1 year) reported significantly more anxiety, more diabetes related distress and less confidence in carrying out self-management tasks, when compared to usual care patients (disease duration < 1 year). Intensive patients with a longer disease duration (> 2 years) showed less anxiety and more self-efficacy. Usual care patients with a longer diabetes duration (> 2 years) reported more distress and less self-efficacy. He concluded that early detection and intensive treatment is not without costs on quality of life. However in the long term an intensive treatment may lead to better psychological outcomes.

A path-model of psychological factors in patients with diabetes and their importance for quality of life and metabolic control was presented by Dr Mathias Rose (Germany). In this model self efficacy and a positive personality disposition were the most important factors for health related quality of life and active

coping behavior. Active coping behavior was the most important psychosocial factor in relation to favorable metabolic control.

The results of the German Multi-centre Diabetes Cohort Study (GMDC-Study), on the initial reaction to type 1 diabetes diagnosis, were presented by Dr Frank Petrak (Germany). In his study a continuous influence of initial coping reactions to diabetes on subsequent quality of metabolic control could be observed. A "doctor-oriented" coping style at the time of diagnosis was related to better metabolic control after three years as well as to greater physical and mental health-related quality of life after two and three years.

Depression in diabetes has a significant negative impact on prognosis, health related costs, quality of life and risk for functional impairment. Therefore knowledge about the aetiology of depression in diabetes as well as detection and screening methods are urgently needed for research as well as for clinical diabetes care. One symposium co-organised by the European Depression in Diabetes (EDID) Consortium and chaired by Dr Arie Nouwen (UK), dealt with these questions.

Dr Gary Law (UK) studied predictors of depressive symptoms in adolescents with type 1 diabetes. In a multivariate analysis he and his collaborators found that the impact of illness beliefs on depressive symptoms was mediated by levels of diabetes distress and social self-efficacy. He stressed the central role of social self-efficacy in understanding and helping to ameliorate adolescent depression in diabetes. Peer support influences depression in adolescents with type 1 diabetes only to the extent that it can promote a sense of social efficacy.

The use of the Problem Areas in Diabetes questionnaire, an inventory to assess diabetes-related distress, for screening for depression was investigated in a study carried out by Norbert Hermanns and his colleagues (Germany). Receiver Operating Curves provided a good screening performance of the PAID, leading to the conclusion that the assessment of diabetes-related distress could be very useful to assess emotional problems related to diabetes as well as depression.

Dr Frans Pouwer (The Netherlands) looked at the identification of depression and diabetes-specific emotional problems by diabetes nurse specialists working in an outpatient diabetes clinic. His study group found rather low recognition rates of these problems. In patients with moderate to severe levels of anxiety or depression, the presence of an emotional problem was recorded in medical charts in only 20-25% of cases. The identification rate of diabetes-specific emotional distress ranged from 0% (treatment-related problems) to 29% (diabetes-related emotional problems). Dr Pouwer suggested future studies should investigate whether re-

cognition and subsequent treatment of emotional problems in diabetes patients can be facilitated by utilizing validated, standardized self-report questionnaires.

The effectiveness of a psycho-educational intervention to increase treatment acceptance and improve depressive symptoms in patients with diabetes was studied by Dr Mirjana Pibernik-Okanovic and her colleagues (Croatia). Preliminary results were presented and the question of 'is it justified to treat clinically and sub-clinically depressed patients in the same way?' was raised. Another matter for discussion was whether individual counselling might be more acceptable than group work in sub-clinical depressed patients.

The PSAD meeting this year also included an interactive Poster session (chaired by Norbert Hermanns, Germany) and a 'Work in Progress' session (chaired by Frans Pouwer, The Netherlands), in which researchers discussed their plans and ideas for future studies with other leading researchers of the field.

The PSAD/NOVO Award is given to outstanding researchers in psychosocial science. This year Dr Marie Clarke (UK) received this award from Dr Chas Skinner (chair of the review committee) for her research: "Effects of a tailored lifestyle self-management intervention in patients with type 2 diabetes" (British Journal of Health Psychology, 2004, 9, 365-9). Her research demonstrated that a brief, tailored, behavioural, self-management intervention had significant long term effects on dietary changes, diabetes related self-care and BMI and waist measurements compared to a control group.

The PSAD study group meeting was preceded by the Second International DAWN Consensus meeting on psychosocial guidelines in diabetes organized by PSAD and Novo Nordisk in cooperation with IDF. After the presentation of the key implications of the global DAWN (Diabetes Attitudes Wishes and Needs) study by Prof. Mark Peyrot (USA) and Sören Skovlund (Denmark), expert workshops focussed on finalising consensus recommendations for psycho-social treatment guidelines in diabetes and proposing key steps needed to promote national implementation. The meeting inspired formulation of general psychosocial recommendations for upcoming global treatment guidelines in diabetes and an actionable framework for implementation of psychosocial assessments, monitoring and training in diabetes care in Europe. A multi-national research frame work for the evaluation of benefits of psychosocial interventions was considered a vital element of concerted action. Effective implementation of new psychosocial treatment guidelines and the DAWN Call to Action was considered of great importance which should be supported by national initiatives and partnerships for maximum reach. Pilot

programs for monitoring quality of life in daily care and psychosocial training workshops for healthcare professionals were identified as feasible next steps in several countries.

Besides the scientific programme the City of Wuerzburg, founded 1300 years ago, provided an ideal location for an introduction into the baroque life style. A City walk guided by the Wuerzburg night-watchman, wine tasting in the former Prince Bishops wine cellar in the Residence Palace, and an introduction into modern art surrounded the serious scientific effort of PSAD participants.

At the end of the meeting Dr Norbert Hermanns (local organiser of this meeting and Chair of the PSAD), expressed, on behalf of the PSAD, his thanks to Novo Nordisk for their generous support of this 10th Scientific Spring Meeting of the PSAD.

The PSAD provides an excellent forum for presentations by experienced and more junior researchers alike. New members are welcome to apply for membership at the same time as the abstract deadline for our next Spring Scientific Meeting, which will be held in Italy, 25–26 April 2006. For further information, visit to the

PSAD website ([www.emgo.nl/psad](http://www.emgo.nl/psad)) or contact the Honorary Secretary:

Norbert Hermanns, PhD, Chairperson, PSAD, and  
Cathy E. Lloyd PhD, Honorary Secretary of the PSAD

Address for correspondence:

Cathy Lloyd, PhD  
School of Health and Social Welfare  
The Open University  
Walton Hall  
Milton Keynes, MK7 6AA  
UK  
Email: [C.E.Lloyd@open.ac.uk](mailto:C.E.Lloyd@open.ac.uk)

Travel grants are awarded each year to junior members and those from Eastern European countries on a competitive basis. Applications are made at the time of submission of abstracts (date to be announced). The PSAD Novo Nordisk Research Award (details available from the Honorary Secretary) will be awarded to the sole or main author of an outstanding peer-reviewed paper furthering our understanding of the psychosocial aspects of diabetes.

## **European Foundation for the Study of Diabetes (EFSD) and sanofi-aventis**

### **European Programme for the funding of studies on the management of diabetes and blood glucose abnormalities in patients suffering an acute cardiovascular event**

**Request for Applications**

### **EFSD and sanofi-aventis announce research funding of up to Euro 1,500,000**

#### **Background**

The European Association for the Study of Diabetes (EASD) was founded in Montecatini, Italy, in 1965. In 1999, the Association created the **European Foundation for the Study of Diabetes (EFSD)**. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.

The sanofi-aventis Group is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas. Their commitment to diabetes medicine has been longstanding since 1923 and the involvement of Hoechst, a legacy company of sanofi-aventis. Today sanofi-aventis produces several medicines to treat diabetes including the number 1 selling insulin in the world. With a dedicated team of research scientists devoted to diabetes research, it is entirely appropriate that the company partners with EFSD to support further research in this field.

#### **Emphasis of Research Project**

Applications to the programme should address topics which are covered by the programme's headline "studies on the management of diabetes and blood glucose abnormalities in patients suffering an acute cardiovascular event". Applications from studies

measuring parameters of cardiac function, endothelial function or lipid metabolism in acute cardiovascular disease before and after insulin treatment compared to other treatments, or comparing different insulin treatment regimens will be specially considered, as will studies focusing on pharmaco-epidemiology and patient care, e.g. evaluating the use of different treatment strategies in various countries and health care settings.

#### **Funding**

The programme will fund up to five clinical research projects, each of up to Euro 300,000. According to the duration and timetable of the projects, funds will be made available annually. The continuance of funding will depend on recipients providing an annual progress report, which will be evaluated by EFSD. All budgets are to be prepared in Euro.

#### **Mechanism of Support and Review**

Applications for this EFSD/sanofi-aventis grant are invited from single non-profit institutions or groups of such institutions from Europe or associated countries. The principal investigator and any co-investigators must be normally employed at a non-profit institution and the study must be performed at such a place of work.

Applications will be subject to scientific review by a specialised ad hoc committee. It is anticipated that

applications will be received, reviewed and the successful project approved for funding by June 2006.

Prior to any final decision on funding, and in order to offer applicants the opportunity to benefit from the review process, EFSD reserves the right to request revision to applications in accordance with the recommendations of the review committee.

#### **Application forms may be requested from:**

Foundation@easd.org

All applications must be prepared on the official forms and completed in strict accordance with the detailed instructions to be found on these forms. In particular, applicants are reminded that any pages in addition to the maximum of 10 allowed for the scientific section of the application will be deleted prior to review. Additional material (in the form of an appendix, attachment, reprints, etc.) is not permitted and will not be sent to reviewers.

Applications should be submitted by post no later than 10 April 2006 (date of receipt) to:

Dr Viktor Jörgens  
Executive Director  
**European Foundation for the Study of Diabetes**  
Rheindorfer Weg 3  
D-40591 Düsseldorf  
Germany  
Tel: + 49-211-75 84 69-0  
Fax: + 49-211-75 84 69 29  
E-mail: Foundation@easd.org

#### **Review Considerations**

Completed applications will be evaluated in accordance with the criteria stated below for scientific/technical merit by an appropriate scientific committee convened by EFSD and sanofi-aventis.

Review criteria are as follows:

- **Significance:** Is the study relevant to the programme? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of the proposed studies on the concepts or methods that drive this field?

- **Approach:** Are the conceptual framework, design, methods and analyses adequately developed, well integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics?
- **Innovation:** Does the project employ novel concepts, approaches or methods? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies?
- **Investigator:** Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)?
- **Environment:** Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support?
- **Relevance:** A brief statement of the impact of the proposed study on diabetes research within the framework of the Programme's plan and objectives.

#### **Reporting Requirements**

The principal investigator funded by this grant is required to submit a scientific report at the end of the funding period. Support by the EFSD/sanofi-aventis research grant must be acknowledged in all publications and communications.

#### **Schedule**

Announcement: January 2006  
Application Deadline: 10 April 2006  
Anticipated Award: June 2006

Enquiries should be directed to:

**Viktor Jörgens, M.D., Executive Director**  
**European Foundation for the Study of Diabetes**  
**Rheindorfer Weg 3**  
**D-40591 Düsseldorf, Germany**  
**Tel: + 49-211-75 84 69-0**  
**Fax: + 49-211-75 84 69 29**  
**E-mail: Foundation@easd.org**

## **European Foundation for the Study of Diabetes (EFSD) and sanofi-aventis**

### **European Programme The Endocannabinoid System from Bench to Bedside**

**Request for Applications**

### **EFSD and sanofi-aventis announce research funding of up to Euro 600,000**

#### **Background**

The European Association for the Study of Diabetes (EASD) was founded in Montecatini, Italy, in 1965. In 1999, the Association created the **European Foundation for the Study of Diabetes (EFSD)**. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.

The sanofi-aventis Group is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas. Their commitment to diabetes medicine has been longstanding since 1923 and the involvement of Hoechst, a legacy company of sanofi-aventis. Today sanofi-aventis produces several medicines to treat diabetes including the number 1 selling insulin in the world. With a dedicated team of research scientists devoted to diabetes research, it is entirely appropriate that the company partners with EFSD to support further research in this field.

#### **Emphasis of Research Project**

Projects should focus on the integration of central and peripheral control of fuel and energy metabolism, and the role in the pathophysiology of multiple cardiometabolic risk factors including insulin resistance and type 2 diabetes, with particular emphasis on the following:

- molecular mechanisms of the endocannabinoid system (ECS) activations under conditions of nutrient overload at the cellular level;
- effects of genetic manipulation of the ECS on integrated physiology in pre-clinical models;
- parameters of pancreatic and gastrointestinal function regulated by the ECS;
- the role of genetic variability in human populations in modulating the role of the ECS in the pathophysiology of insulin resistance, insulin secretory function and type 2 diabetes.

Studies focusing on pharmaco-epidemiology and patient care will be specially considered.

#### **Funding**

The programme will fund up to three projects, each of up to Euro 100,000, from either a clinical or basic research background.

In addition, one clinical research project of up to Euro 300,000 over a period of three years will be funded. The continuance of funding will depend upon recipients providing an annual progress report, which will be evaluated by EFSD.

All budgets are to be prepared in Euro.



## **Mechanism of Support and Review**

Applications for this EFSD/sanofi-aventis grant are invited from single non-profit institutions or groups of such institutions from Europe or associated countries. The principal investigator and any co-investigators must be normally employed at a non-profit institution and the study must be performed at such a place of work.

Applications will be subject to scientific review by a specialised ad hoc committee. It is anticipated that applications will be received, reviewed and the successful project approved for funding by June 2006.

Prior to any final decision on funding, and in order to offer applicants the opportunity to benefit from the review process, EFSD reserves the right to request revision to applications in accordance with the recommendations of the review committee.

### **Application forms may be requested from:**

Foundation@easd.org

All applications must be prepared on the official forms and completed in strict accordance with the detailed instructions to be found on these forms. In particular, applicants are reminded that any pages in addition to the maximum of 10 allowed for the scientific section of the application will be deleted prior to review. Additional material (in the form of an appendix, attachment, reprints, etc.) is not permitted and will not be sent to reviewers.

Applications should be submitted by post no later than 10 April 2006 (date of receipt) to:

Dr Viktor Jörgens  
Executive Director  
**European Foundation for the Study of Diabetes**  
Rheindorfer Weg 3  
D-40591 Düsseldorf  
Germany  
Tel: + 49-211-75 84 69-0  
Fax: + 49-211-75 84 69 29  
E-mail: Foundation@easd.org

## **Review Considerations**

Completed applications will be evaluated in accordance with the criteria stated below for scientific/technical merit by an appropriate scientific committee convened by EFSD and sanofi-aventis.

Review criteria are as follows:

- **Significance:** Is the study relevant to the programme? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of the proposed studies on the concepts or methods that drive this field?
- **Approach:** Are the conceptual framework, design, methods and analyses adequately developed, well integrated, and appropriate to the aims of the project?  
Does the applicant acknowledge potential problem areas and consider alternative tactics?
- **Innovation:** Does the project employ novel concepts, approaches or methods? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies?
- **Investigator:** Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)?
- **Environment:** Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support?
- **Relevance:** A brief statement of the impact of the proposed study on diabetes research within the framework of the Programme's plan and objectives.

## **Reporting Requirements**

The principal investigator funded by this grant is required to submit a scientific report at the end of the funding period. Support by the EFSD/sanofi-aventis research grant must be acknowledged in all publications and communications.

## **Schedule**

Announcement: January 2006  
Application Deadline: 10 April 2006  
Anticipated Award: June 2006

Enquiries should be directed to:

**Viktor Jörgens, M.D., Executive Director**  
**European Foundation for the Study of Diabetes**  
Rheindorfer Weg 3  
D-40591 Düsseldorf, Germany  
Tel: + 49-211-75 84 69-0  
Fax: + 49-211-75 84 69 29  
E-mail: Foundation@easd.org

**European Foundation for the Study of Diabetes (EFSD)  
and  
Amylin Pharmaceuticals Inc.**

**Paul Langerhans Grant  
Integrated physiology of the entero-insular axis  
and the brain in metabolic homeostasis**

**Request for Applications**

**EFSD and Amylin  
announce  
1 Grant of Euro 100,000 in 2006**

**Background**

The European Association for the Study of Diabetes (EASD) was founded in Montecatini, Italy, in 1965. In 1999, the Association created the **European Foundation for the Study of Diabetes (EFSD)**. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialisation of innovative medicines. The company was founded in 1987 on the discovery of a hormone, amylin, produced by the same beta cells of the pancreas that make insulin. Since then, Amylin has built a strong foundation on research and development. Amylin currently has two first in class diabetes drugs approved and marketed in the United States.

This grant honours the memory of Paul Langerhans, who discovered the islet cells of the pancreas.

**Plan**

**EFSD and Amylin** have established a new **partnership for studies on integrated physiology of the entero-insular axis and the brain in metabolic homeostasis**, to encourage new projects aimed at advancing current knowledge in this domain. The Programme invites applications from non-profit organisations.

To achieve the goals and objectives of this Programme, EFSD and Amylin invite applications by issuing this

“Request for Applications” (RFA), which indicates joint funding as well as areas of research emphasis.

The EFSD/Amylin Paul Langerhans Programme Award is intended to stimulate and accelerate European research aimed at improved understanding of the physiology of the entero-insular axis and the brain in metabolic homeostasis.

**Funding**

In 2006 one grant of Euro 100,000 is available.

**Mechanism of Support and Review**

Research will be supported through the award of a fixed sum grant of Euro 100,000. The duration of each award may be one year or longer, depending upon the needs of the project and as justified in the application, so long as the total budget does not exceed the fixed sum of Euro 100,000. The Programme Board, on advisement from the Review Committee, may on occasion and at its discretion recommend an award in a lesser amount considered more appropriate for the proposed studies.

Applications for an EFSD/Amylin Paul Langerhans Programme Award are invited from single non-profit institutions or groups of such institutions from Europe and associated countries. The principal investigator and any co-investigators must be normally employed at a non-profit institution and the study must be performed at such a place of work.

Applications will be subject to scientific review by a specialised ad hoc committee. Funding will require

approval by a joint EFSD and Amylin board convened for this purpose. It is anticipated that applications for the grant year 2006 will be received, reviewed and approved for funding by May 2006.

### **Research Grant Applications**

Applications for research grants may be subjected to pre-review (or triage) procedures. In this event, any application rejected at pre-review will not be subject to a complete scientific review. The deadline for receipt of research grant applications for funding in 2006 is 15 March 2006.

Research grants for the purposes of this Programme are limited to Euro 100,000. All budgets are to be prepared in Euro. For countries in which the Euro is not yet the common currency, the exchange rate (between the Euro and the local currency in the country where the work is to be performed) used for calculating the Euro budget must be mentioned under "Budget Justification". EFSD and Amylin reserve the right to increase or decrease approved funding in Euro amounts to compensate for any significant change in the exchange rate.

### **Application forms may be requested from:**

Foundation@easd.org

All applications must be prepared on the official forms and completed in strict accordance with the detailed instructions to be found on these forms. In particular, applicants are reminded that any pages in addition to the maximum of 10 allowed for the scientific section of the application will be deleted prior to review. Similarly, no applications using a font or line-spacing smaller than that defined in the instructions will be considered for review. Additional material (in the form of an appendix, attachment, reprints, etc.) is not receivable and will not be sent to reviewers.

Applications should be submitted by **15 March 2006** (date of receipt) to:

Viktor Jörgens, M.D., Executive Director  
**European Foundation for the Study of Diabetes**  
 Rheindorfer Weg 3  
 D-40591 Düsseldorf, Germany

### **Review Considerations**

Completed applications will be evaluated in accordance with the criteria stated below for scientific/technical merit by an appropriate scientific committee convened by EFSD.

Review criteria are as follows:

- **Significance:** Does the study address an important problem in keeping with the goals and focus areas of this EFSD/Amylin partnership programme? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of the proposed studies on the concepts or methods that drive this field?
- **Approach:** Are the conceptual framework, design, methods and analyses adequately developed, well integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics?
- **Innovation:** Does the project employ novel concepts, approaches or methods? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies?
- **Investigator:** Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)?
- **Environment:** Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support?
- **Relevance:** A brief statement of the impact of the proposed study on integrated physiology of the entero-insular axis and the brain in metabolic homeostasis

### **Reporting Requirements**

All investigators funded by this Programme are required to submit a scientific report at the end of the funding period.

### **Schedule**

Announcement: January 2006  
 Application Deadline: 15 March 2006  
 Anticipated Award: May 2006

Enquiries should be directed to:

**Viktor Jörgens, M.D., Executive Director**  
**European Foundation for the Study of Diabetes**  
 Rheindorfer Weg 3  
 D-40591 Düsseldorf, Germany  
 Tel: + 49-211-75 84 69-0  
 Fax: + 49-211-75 84 69 29  
 E-mail: Foundation@easd.org

## European Foundation for the Study of Diabetes (EFSD) and Merck Sharp & Dohme (MSD)

### European Studies on Beta Cell Function and Survival

#### Request for Applications

## EFSD and MSD announce up to 8 Grants of Euro 100,000 this year

### **Background**

The European Association for the Study of Diabetes (EASD) was founded in Montecatini, Italy, in 1965. In 1999, the Association created the **European Foundation for the Study of Diabetes (EFSD)**. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.

Merck & Co., Inc is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. **Merck Sharp & Dohme, or MSD**, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

### **Plan**

**EFSD and MSD** have established a new **European Study Programme on Beta Cell Function and Survival** to encourage new projects (basic and clinical) aimed at advancing current knowledge in this domain. The Programme invites applications from non-profit organisations.

To achieve the goals and objectives of this Programme, EFSD and MSD invite applications by issuing this "Request for Applications" (RFA), which indicates joint funding as well as areas of research emphasis.

The EFSD/MSD Programme Awards are intended to stimulate and accelerate European basic and clinical

research into all aspects of beta cell function and survival, with particular focus on the following:

- increasing beta cell mass/function
- mechanisms of glucose-stimulated insulin secretion
- mechanisms of beta cell dysfunction in type 2 diabetes, including beta cell gluco- and lipotoxicity
- non-invasive imaging of beta cells
- beta cell intermediary metabolism
- clinical research directed towards an understanding of the loss of beta cell mass and impaired beta cell function is an especially high priority area

### **Funding**

Up to 8 grants, each of Euro 100,000, will be made available this year.

### **Mechanism of Support and Review**

Research will be supported through the award of fixed sum grants, each of up to Euro 100,000. The duration of each award may be one year or longer, depending upon the needs of the project – which may include basic research and clinical investigation - and as justified in the application, so long as the total budget does not exceed the fixed sum of Euro 100,000. The Programme Board, at the suggestion of the Review Committee, may at its discretion recommend an award in a lesser (or in some cases greater) amount considered more appropriate for the proposed studies.

Applications for an EFSD/MSD Programme Award are invited from single non-profit institutions or groups of such institutions from Europe and associated countries. The principal investigator and any co-investigators must

be normally employed at a non-profit institution and the study must be performed at such a place of work.

Applications will be subject to scientific review by a specialised ad hoc committee. Funding will require approval by a joint EFSD and MSD board convened for this purpose. It is anticipated that applications for this year will be received, reviewed and approved for funding by June 2006.

### **Research Grant Applications**

Applications for research grants may be subjected to pre-review (or triage) procedures. In this event, any application rejected at pre-review will not be subject to a complete scientific review.

The deadline for receipt of research grant applications is **20 April 2006**.

The budget of research grants for the purposes of this Programme is limited to **Euro 100,000**. All budgets are to be prepared in Euro. For countries in which the Euro is not yet the common currency, the exchange rate (between the Euro and the local currency in the country where the work is to be performed) used for calculating the Euro budget must be mentioned under "Budget Justification".

### **Application forms may be requested from:**

Foundation@easd.org

All applications must be prepared on the official forms and completed in strict accordance with the detailed instructions to be found on these forms. In particular, applicants are reminded that any pages in addition to the maximum of 10 allowed for the scientific section of the application will be deleted prior to review. Similarly, no applications using a font or line-spacing smaller than that defined in the instructions will be considered for review. Additional material (in the form of an appendix, attachment, reprints, etc.) is not receivable and will not be sent to reviewers.

Applications should be submitted by 20 April 2006 (date of receipt) to:

Viktor Jörgens, M.D., Executive Director  
**European Foundation for the Study of Diabetes**  
 Rheindorfer Weg 3  
 D-40591 Düsseldorf, Germany

### **Review Considerations**

Completed applications will be evaluated in accordance with the criteria stated below for scientific/technical

merit by an appropriate scientific committee convened by EFSD and MSD.

Review criteria are as follows:

- **Significance:** Does the study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of the proposed studies on the concepts or methods that drive this field?
- **Approach:** Are the conceptual framework, design, methods and analyses adequately developed, well integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics?
- **Innovation:** Does the project employ novel concepts, approaches or methods? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies?
- **Investigator:** Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)?
- **Environment:** Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support?
- **Relevance:** A brief statement of the impact of the proposed study on beta cell function and survival.

### **Reporting Requirements**

All investigators funded by this Programme are required to submit a scientific report at the end of the funding period.

### **Schedule**

Announcement: January 2006  
 Application Deadline: 20 April 2006  
 Anticipated Award: June 2006

Enquiries should be directed to:

Viktor Jörgens, M.D., Executive Director  
**European Foundation for the Study of Diabetes**  
 Rheindorfer Weg 3  
 D-40591 Düsseldorf, Germany  
 Tel: + 49-211-75 84 69-0  
 Fax: + 49-211-75 84 69 29  
 E-mail: Foundation@easd.org

# European Foundation for the Study of Diabetes (EFSD) and LifeScan

## European Studies on Glucose Monitoring

### Request for Applications

## EFSD and LifeScan announce 2 Grants of Euro 100,000 this year

### **Background**

The European Association for the Study of Diabetes (EASD) was founded in Montecatini, Italy, in 1965. In 1999, the Association created the **European Foundation for the Study of Diabetes (EFSD)**. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.

For more than two decades LifeScan has been committed to improving the quality of life for people with diabetes. LifeScan pioneered the modern era of blood glucose monitoring, and helped bring blood glucose testing out of the laboratory and into the hands of patients. That change significantly empowered people with diabetes to manage their condition and live more normal lives. In 1986 Johnson & Johnson acquired LifeScan. Today, headquartered in Milpitas, California, LifeScan has manufacturing facilities in Milpitas, Puerto Rico and Inverness, Scotland, and has more than 2500 employees worldwide.

### **Plan**

EFSD and LifeScan have established a **Partnership for European Studies on Glucose Monitoring** to encourage new projects aimed at advancing current knowledge in this domain. The Programme invites applications from non-profit organisations.

To achieve the goals and objectives of this Programme, EFSD and LifeScan invite applications by issuing this "Request for Applications" (RFA), which indicates joint funding as well as areas of research emphasis.

The EFSD/LifeScan Study Programme Awards are intended to stimulate and accelerate European research aimed at improved understanding of the optimal use of glucose monitoring tools both in type 1 and type 2 diabetes, with particular focus on the following:

- impact of glucose monitoring on diabetes outcomes (specifically in type 2 diabetes) and/or diabetes therapy (including but not limited to: compliance, quality of life);
- optimal/appropriate frequency of testing in different target populations (and the value of preprandial versus postprandial testing);
- new technologies in glucose monitoring (including but not limited to: continuous monitoring, minimal and non-invasive monitoring) and their clinical interest in diabetes practice;
- impact of glucose monitoring on health economics;
- physiology of alternative site testing (including but not limited to: differences in glucose concentration between different capillary beds of finger and alternative sites, differences between glucose concentration in blood, interstitial fluid and other compartments) and its impact on the use of glucose monitoring systems;
- informatics systems in support of glucose monitoring tools (including but not limited to: role of software, telemedicine, algorithms);
- glucose monitoring in children.

### **Funding**

In 2006 two grants each of Euro 100,000 are available.

### **Mechanism of Support and Review**

Research will be supported through the award of fixed sum grants, each of Euro 100,000. The duration of each award may be one year or longer, depending upon the needs of the project and as justified in the application, so long as the total budget does not exceed the fixed sum of Euro 100,000. The Programme Board, on advisement from the Review Committee, may on occasion and at its discretion recommend an award in a lesser amount considered more appropriate for the proposed studies.

Applications for an EFSD/LifeScan Programme Award are invited from single non-profit institutions or groups of such institutions from Europe and associated countries. The principal investigator and any co-investigators must be normally employed at a non-profit institution and the study must be performed at such a place of work.

Applications will be subject to scientific review by a specialised ad hoc committee. Funding will require approval by a joint EFSD and LifeScan board convened for this purpose. It is anticipated that applications for the grant year 2006 will be received, reviewed and approved for funding by June 2006.

### **Research Grant Applications**

Applications for research grants may be subjected to pre-review (or triage) procedures. In this event, any application rejected at pre-review will not be subject to a complete scientific review. The deadline for receipt of research grant applications this year is 25 April 2006.

Research grants for the purposes of this Programme are limited to **Euro 100,000**. All budgets are to be prepared in Euro. For countries in which the Euro is not yet the common currency, the exchange rate (between the Euro and the local currency in the country where the work is to be performed) used for calculating the Euro budget must be mentioned under "Budget Justification". EFSD and LifeScan reserve the right to increase or decrease approved funding in Euro amounts to compensate for any significant change in the exchange rate.

### **Application forms may be requested from:**

Foundation@easd.org

All applications must be prepared on the official forms and completed in strict accordance with the detailed instructions to be found on these forms. In particular, applicants are reminded that any pages in addition to the maximum of 10 allowed for the scientific section of the application will be deleted prior to review. Similarly, no applications using a font or line-spacing smaller than that defined in the instructions will be considered for review. Additional material (in the form of an appendix, attachment, reprints, etc.) is not receivable and will not be sent to reviewers.

Applications should be submitted by 25 April 2006 (date of receipt) to:

Viktor Jörgens, M.D., Executive Director  
**European Foundation for the Study of Diabetes**  
 Rheindorfer Weg 3  
 D-40591 Düsseldorf, Germany

### **Review Considerations**

Completed applications will be evaluated in accordance with the criteria stated below for scientific/technical merit by an appropriate scientific committee convened by EFSD.

Review criteria are as follows:

- **Significance:** Does the study address an important problem in keeping with the goals and focus areas of this EFSD/LifeScan partnership programme? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of the proposed studies on the concepts or methods that drive this field?
- **Approach:** Are the conceptual framework, design, methods and analyses adequately developed, well integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics?
- **Innovation:** Does the project employ novel concepts, approaches or methods? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies?
- **Investigator:** Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)?
- **Environment:** Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support?
- **Relevance:** A brief statement of the impact of the proposed study on glucose monitoring.

### **Reporting Requirements**

All investigators funded by this Programme are required to submit a scientific report at the end of the funding period.

### **Schedule**

Announcement: January 2006  
 Application Deadline: 25 April 2006  
 Anticipated Award: June 2006

Enquiries should be directed to:

**Viktor Jörgens, M.D., Executive Director**  
**European Foundation for the Study of Diabetes**  
 Rheindorfer Weg 3  
 D-40591 Düsseldorf, Germany  
 Tel: + 49-211-75 84 69-0  
 Fax: + 49-211-75 84 69 29  
 E-mail: Foundation@easd.org

## Announcements:

### **Third Madras Diabetes Research Foundation (MDRF) - American Diabetes Association (ADA) Postgraduate Course on Diabetes Chennai, India, 29 September – 1 October 2006**

For further details, please contact:

Dr V. Mohan, M.D., FRCP, Ph.D., D.Sc.  
Madras Diabetes Research Foundation & Dr. Mohan's  
Diabetes Specialities Centre  
No. 4 Conran Smith Road,  
Gopalapuram,  
Chennai 600 086  
India.

Tel: +91 44 28359048, 28359051, 28353351

Fax: +91 44 28350935

E-mail: mvdsc@vsnl.com

Also visit our website at [www.mdrf-ada.com](http://www.mdrf-ada.com) or [www.drmoahnsdiabetes.com](http://www.drmoahnsdiabetes.com) for details regarding registration etc.

### **XIV International Symposium on ATHEROSCLEROSIS Rome, Italy, 18-22 June, 2006**

Congress President: C.R. Sirtori (Italy), Congress Vice-President: E. Mannarino (Italy), Honorary President: R. Paoletti (Italy)

List of topics:

Epidemiology of cardiovascular disease; basic science; pathophysiology of lipids and lipoproteins; pharmacological control of lipids and lipoproteins, optimal atherosclerosis management: diabetes and atherosclerosis, obesity, hypertension and atherosclerosis, anti-atherothrombotic therapy, pharmacogenetics of antiatherothrombotic drugs, new areas of investigation; metabolic syndrome; nutritional approaches; diagnostic technolgis for arterial diseases; novel technologies for risk determination; biomarkers; pathophysiology of thrombosis; gene therapy and stem cells; clinical aspects; clinical practice

**Contributed Papers – Call for Abstracts (Oral and Poster Presentation):** Abstracts must be sent to the Scientific-Organising Secretariat by 9 January, 2006.

**Internet:** Home page for the Symposium is located at [www.isa2006.org](http://www.isa2006.org)

**Scientific-Organizing Secretariat:**  
ISA 2006 – Fondazione Giovanni Lorenzini  
Via A. Appiani 7  
20121 Milan  
Italy  
Tel: +39-02-29006267  
Fax: +39-02-29007018  
E-mail: [info@isa2006.org](mailto:info@isa2006.org)

### **The Sixth International Conference on Insulin Action and Insulin Resistance Serengeti, Tanzania, 25 Nov – 2 December, 2006**

For further information, please contact:

Boris Draznin, MD PhD  
E-mail: [boris.draznin@med.va.gov](mailto:boris.draznin@med.va.gov)  
Tel: +1-303-393-4619  
Fax: +1-303-377-5686

### **11th Scientific Meeting of the EASD Hypertension in Diabetes (HID) Study Group (HID 2006) Belgrade, Serbia, 6-8 April 2006**

Local organiser:  
Dr Svetlana Jelic

Abstract submission deadline:  
**15 February 2006**

Abstracts should be sent, preferably by e-mail, to:

Dr Rita Rahmani  
Secretary EASD-HID Study Group  
10 Hatabak st.  
Oranit  
44813 Israel  
E-mail: [rahmani@post.tau.ac.il](mailto:rahmani@post.tau.ac.il)



# European Association for the Study of Diabetes

## EASD Executive Committee

President:	E. Ferrannini, Pisa (retires 2007)
Vice-President:	U. Smith, Göteborg (retires 2008)
Vice-President:	E. Standl, Munich (retires 2006)
Honorary Secretary:	D. L. Eizirik, Brussels (retires 2007)
Honorary Treasurer:	J. Škrha, Prague (retires 2006)
Chairman of the Postgraduate Education Sub-Committee:	T. Pieber, Austria (retires 2008)
Editor-in-Chief, DIABETOLOGIA:	E. Gale, Bristol (retires 2007)

**EASD Council comprises of the Officers above and the following members:**

<b>Term Expiring September 2006</b>	<b>Term Expiring September 2007</b>	<b>Term Expiring September 2008</b>
I. Gourieva, Moscow	L. Czupryniak, Lodz	K. Dahl Jørgensen, Oslo
S. Lenzen, Hanover	L. Gardete Correia, Lisbon	R. Heine, Amsterdam
C. Sanjeevi, Stockholm	D. Mauricio, Barcelona	B. Mankovsky, Kiev
J.-L. Selam, Tustin	T. Otonkoski, Helsinki	S. Sasson, Jerusalem

The Past President, P.A. Halban, and the Secretary of the Postgraduate Education Sub-Committee, N.D. Hancu, are members of the Council ex officio.

### HONORARY AUDITORS

N. Katsilambros, Athens and M. Tiedge, Rostock

### HONORARY MEMBERS

G. Alberti, Newcastle – D. Andreani, Rome – W. Creutzfeldt, Göttingen – A. Czyzyk, Warsaw – J.K. Davidson, Atlanta – T. Deckert, Hellerup – P. Freychet, Nice – L.G. Heding, Copenhagen – C. Hellerström, Uppsala – H. Keen, London. – E. Kohner, London – P. Lefèbvre, Liège – R. Luft, Stockholm – C. Lurie, New York – J. Pirart, Brussels – S. Rahbar, Duarte – P. Randle, Oxford – E. Shafir, Jerusalem – D. Steiner, Chicago – E. von Wasielowski, Munich

### GOLD MEMBERS

Astra Zeneca, Macclesfield, UK – Bayer HealthCare, Leverkusen, Germany - Eli Lilly & Co., Indiana, USA – GlaxoSmithKline, Middlesex, UK – LifeScan, Inc., California, USA – Merck & Co. Inc., New Jersey, USA – Novartis Pharma AG, Basel, Switzerland – Novo Nordisk A/S, Bagsvaerd, Denmark – Pfizer, Inc, New York, USA – sanofi-aventis, Paris, France – Servier, Neuilly-sur-Seine, France – Takeda Chemical Industries Ltd., Osaka, Japan

### SILVER MEMBERS

Abbott Laboratories GmbH, Wiesbaden, Germany – Johnson & Johnson, New Jersey, USA – Merck KGaA, Darmstadt, Germany – Sankyo Pharma GmbH, Munich, Germany - Sooil Development Co., Ltd., Seoul, Korea

### ASSOCIATE MEMBERS

Amylin Europe Ltd., Oxford, UK – Animas Corporation, Pennsylvania, USA – A. Menarini Diagnostics, Grassano, Italy – Becton Dickinson Consumer Healthcare Europe, Pont-de-Claix, France – Berlin Chemie AG, Berlin, Germany – Boehringer Ingelheim GmbH, Ingelheim, Germany – HemoCue AB, Angelholm, Sweden – Medtronic Europe, Brussels, Belgium – Nipro Diabetes Systems, Florida, USA – Owen Mumford Ltd., Oxford, UK – Roche Diagnostics GmbH, Mannheim, Germany – Smiths Medical MD, Inc., Minnesota, USA – Ypsomed GmbH, Sulzbach, Germany

The EASD Executive Committee is also the Executive Committee of the European Foundation for the Study of Diabetes (EFSD)

#### *EASD Secretariat:*

Executive Director: V. Jörgens  
M. Grüßer, M. Hata,  
A. Klee, P. Nani,  
K. Page, C. Persidis, R. Sautter  
*EFSD:* S. Burgess

#### *Office:*

Rheindorfer Weg 3  
D-40591 Düsseldorf, Germany  
Tel: +49-211-758469-0  
Fax: +49-211-758469-29  
secretariat@easd.org  
[www.easd.org](http://www.easd.org)

### FUTURE MEETINGS

14–17 September 2006: Copenhagen/Malmoe; 17–21 September 2007: Amsterdam;